MBB Public Markets I LLC Purchases 77,575 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

MBB Public Markets I LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 822.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 87,010 shares of the biopharmaceutical company’s stock after acquiring an additional 77,575 shares during the quarter. MBB Public Markets I LLC’s holdings in Gilead Sciences were worth $5,970,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. CarsonAllaria Wealth Management Ltd. boosted its position in Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares during the period. Palisade Asset Management LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at approximately $29,000. Cedar Wealth Management LLC boosted its holdings in Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 160 shares during the period. Financial Connections Group Inc. purchased a new position in Gilead Sciences in the 2nd quarter valued at approximately $34,000. Finally, Frank Rimerman Advisors LLC bought a new stake in Gilead Sciences during the 4th quarter valued at $36,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the sale, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock valued at $3,002,940 in the last 90 days. Insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 0.7 %

GILD stock opened at $83.61 on Friday. The company has a market capitalization of $104.17 billion, a PE ratio of 232.25, a price-to-earnings-growth ratio of 2.91 and a beta of 0.18. The company’s 50 day moving average price is $78.05 and its two-hundred day moving average price is $71.58. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. The business had revenue of $6.95 billion for the quarter, compared to analysts’ expectations of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. As a group, analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were issued a dividend of $0.77 per share. The ex-dividend date was Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.68%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on GILD shares. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Robert W. Baird restated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Thursday, June 20th. Royal Bank of Canada upped their price target on Gilead Sciences from $72.00 to $74.00 and gave the company a “sector perform” rating in a research report on Wednesday, September 4th. BMO Capital Markets raised their price objective on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 15th. Twelve research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $82.06.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.